Robert Kile

Predict protein synthesizability and activity with the Tierra Flywheel. Learn how to develop functional proteins in less time and at lower costs from our CEO Michael Nemzek, who will be in San Diego for #BIO2024. Please reach out on the partnering link below. https://lnkd.in/gHWNqxv6 #pharma #proteins #therapeutics #artificialintelligence #largelanguagemodels

4

If you have an hour to kill and want to learn about one of the first biological fungicides registered 2 decades ago, then I suggest watching this webinar. Ps. 20 years later and Actinovate is still widely used and can be found in the IPM shed of many a grower across the USA! Have a question, reach out today!

12

2 Comments

Lamassu BioTech is ready for Biotechnology Innovation Organization’s #BIO2024 Conference! 🔬 Lamassu CEO Gabi Hanna MD., will be in San Diego throughout #BIO2024, meeting with other leaders in the #biotech industry and exploring opportunities to accelerate hope and healing. Lamassu is transforming the way we treat metastatic cancer and solving the critical unmet medical need of severe acute pancreatitis. SA53, a #noveltherapeutic that targets p53 wild-type sarcomas, has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission that was recently approved by the FDA. This potential best-in-class #precisionmedicines offers new hope for #metastitic #cancertreatment. Companies and investors interested in targeted cancer therapies, or anyone interested in learning about our team’s works, should use the contact form on our website, https://lnkd.in/gnvwYBm, to schedule a meeting during #BIO2024.

15

Roche's recent decision to offload their Vacaville facility highlights the increasing importance of cell line productivity in biomanufacturing strategy. According to Dan Stanton of Bioprocess Insider, Roche is moving towards more high titer processes and products with lower volume demands. (You can read the article here https://lnkd.in/erRx597k) Agile manufacturing strategies are enabled by cell line productivity, which allows for the same amount of drug substance to be produced in smaller bioreactors. This, in turn, allows for smaller clean rooms and lower running costs. Just - Evotec Biologics' J.CHO High Expression System cell lines, grown in perfusion bioreactors, produce over 4 g/L of antibody each day, equivalent to around 30 g/L in fed-batch mode (https://lnkd.in/eexeJrQA). This level of productivity allows for commercial quantities of antibody to be manufactured in 1000L single-use bioreactors in our modular J.POD facilities. As a result, large-scale stainless-steel facilities are becoming redundant. The future of biomanufacturing lies in maximizing cell line productivity, and our J.CHO system is leading the way. #biomanufacturing #celllineproductivity #JCHO #JPod #agilemanufacturing 👨‍⚕️Philip Boehme

36

The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions' (EBS.N), opens new tab  smallpox vaccine for use in people at high risk of mpox infection. The FDA clearance, announced late on Thursday by the company, makes the vaccine the second approved shot against mpox in the U.S. after Bavarian Nordic's (BAVA.CO), opens new tab  Jynneos. Emergent, which has a market capitalization of about $471 million, in early August forecast sales of up to $490 million from products that are stockpiled by governments, such as the smallpox vaccine and an anthrax shot. Emergent's vaccine, called ACAM2000, however, cannot be administered to those with weakened immune systems, including people with HIV. It found limited use during the 2022 mpox outbreak in the United States, despite being part of the country's stockpile. Both Jynneos and ACAM2000 contain vaccinia virus that is closely related to, but less harmful than the viruses that cause smallpox and mpox. ACAM2000 uses a live, infectious form of the vaccinia virus. #FDAApproval #SmallpoxVaccine #MpoxPrevention #VaccineDevelopment #PublicHealth #Biotechnology #Immunization #HealthcareInnovation #EmergingInfectiousDiseases #PharmaceuticalResearch https://lnkd.in/giWSdB6U

1

📉 Fed cuts rates, biotech hopeful! 💊 The Federal Reserve's decision to lower interest rates by 0.5% has sparked optimism in the biotech sector, which has faced tough funding conditions. Lower rates are expected to make risky investments in early-stage drug companies more attractive again, potentially boosting biotech valuations and funding. 🌱💸 While this is seen as a positive shift, industry insiders caution that challenges like the upcoming U.S. elections and market cycles remain. Still, many are hopeful this rate cut will inject momentum back into the biotech funding ecosystem! 🚀 #Biotech #InterestRates #Innovation #VentureCapital #Startups #Biopharma #Funding #Investment

11

2 Comments